Urethra-sparing stereotactic body radiotherapy for prostate cancer: How much can the rectal wall dose be reduced with or without an endorectal balloon?
Verbakel W.; Zilli T.; Escude L.; Tsvang L.; Miralbell R.; Björkqvist M.; Pérez-Moreno J.; Ozen Z.; Linthout N.; Rouzaud M.; Dubouloz A.; Lencart J.
Urethra-sparing stereotactic body radiotherapy for prostate cancer: How much can the rectal wall dose be reduced with or without an endorectal balloon?
Verbakel W.
Zilli T.
Escude L.
Tsvang L.
Miralbell R.
Björkqvist M.
Pérez-Moreno J.
Ozen Z.
Linthout N.
Rouzaud M.
Dubouloz A.
Lencart J.
BioMed Central Ltd.
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2021042825745
https://urn.fi/URN:NBN:fi-fe2021042825745
Kokoelmat
- Rinnakkaistallenteet [19207]